Adamis submits NDA for adrenaline product

Adamis Pharmaceuticals (ADMP) submits an NDA for its epinephrine pre-filled single dose syringe (1:1000; 0.3 mg) for the emergency treatment of allergic reactions (Type 1) including anaphylaxis. The company believes its product will be an attractive lower cost substitute versus the more-expensive auto-injectors.

Comments (2)
  • dramorgan
    , contributor
    Comments (59) | Send Message

    For anyone who wants an overview of NDA process.
    29 May 2014, 09:11 AM Reply Like
  • wyattkap
    , contributor
    Comments (43) | Send Message
    MAJOR step in the right direction. AMAZING how few people care about this company. Been too quiet for too long I suppose. Doesn't take away from the massive valuation I see ahead of us. The buying opportunity just got a whole lot better.
    30 May 2014, 04:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs